Multifunctional nanoscale platforms for targeting of the cancer cell immortality spectrum.

In the post-genomic era, "omics" platforms and cancer systems biology are greatly advancing our knowledge of the molecular and cellular underpinnings of cancer. In this article, we begin by outlining the factors governing the development of cancer (tumorigenesis) and use this framework to motivate the need for systems-approaches to cancer diagnostics and therapeutics. We review recent efforts to tap into the remarkable potential of nanotechnology for (i) systems-surveillance (or "sensing") of the molecular signatures of tumorigenesis, and (ii) spatiotemporally-regulated delivery (or "targeting") of combination therapeutics to cancer cells. Specifically, we highlight the salient role of polymeric biomaterials and describe the physicochemical characteristics that render them attractive for the design of such nanoscale platforms. We conclude with discussions on the emerging role of macromolecular biophysics and computational nanotechnology in engineering spatiotemporally-regulated anti-cancer systems.

[1]  M. Nugent,et al.  Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation , 2004, Angiogenesis.

[2]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[3]  Robert Langer,et al.  Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres , 2004, Pharmaceutical Research.

[4]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[5]  Michael L Klein,et al.  Emerging Applications of Polymersomes in Delivery: from Molecular Dynamics to Shrinkage of Tumors. , 2007, Progress in polymer science.

[6]  John C. Bischof,et al.  Enhancement of tumor thermal therapy using gold nanoparticle–assisted tumor necrosis factor-α delivery , 2006, Molecular Cancer Therapeutics.

[7]  R. Bellamkonda,et al.  Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Robert Langer,et al.  Multifunctional nanoparticles for prostate cancer therapy , 2009, Expert review of anticancer therapy.

[9]  May D. Wang,et al.  Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. , 2009, Trends in biotechnology.

[10]  C. Lieber,et al.  Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species , 2001, Science.

[11]  S. Friedlander,et al.  Dynamics of Chain Aggregates of Carbon Nanoparticles in Isolation and in Polymer Films: Implications for Nanocomposite Materials , 2004 .

[12]  T. Park,et al.  In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[13]  A. Sarasin,et al.  An overview of the mechanisms of mutagenesis and carcinogenesis. , 2003, Mutation research.

[14]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[15]  Z. Duan,et al.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.

[16]  C. Astete,et al.  Synthesis and characterization of PLGA nanoparticles , 2006, Journal of biomaterials science. Polymer edition.

[17]  A. Göpferich,et al.  Erosion of composite polymer matrices. , 1997, Biomaterials.

[18]  J. Siepmann,et al.  Mathematical modeling of bioerodible, polymeric drug delivery systems. , 2001, Advanced drug delivery reviews.

[19]  Raul E Cachau,et al.  In-silico nanobio-design. A new frontier in computational biology. , 2007, Current topics in medicinal chemistry.

[20]  C. Berkland,et al.  Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration , 2009, Pharmaceutical Research.

[21]  Robert Langer,et al.  Advancing the field of drug delivery: taking aim at cancer. , 2003, Cancer cell.

[22]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[23]  Chad A Mirkin,et al.  Nanostructures in biodiagnostics. , 2005, Chemical reviews.

[24]  Shiladitya Sengupta,et al.  A dual‐color fluorescence imaging‐based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[26]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[27]  Sunita Yadav,et al.  Multi-functional nanocarriers to overcome tumor drug resistance. , 2008, Cancer treatment reviews.

[28]  M. Blasco Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.

[29]  S. Schwendeman,et al.  Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.

[30]  K. Dixon,et al.  Genetic alterations and DNA repair in human carcinogenesis. , 2004, Seminars in cancer biology.

[31]  R. Leonard,et al.  Capecitabine and Docetaxel Combination for the Treatment of Breast Cancer , 2008, Women's health.

[32]  C. Larabell,et al.  Quantum dots as cellular probes. , 2005, Annual review of biomedical engineering.

[33]  R. Kerbel,et al.  A role for survivin in chemoresistance of endothelial cells mediated by VEGF , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Gengfeng Zheng,et al.  Multiplexed electrical detection of cancer markers with nanowire sensor arrays , 2005, Nature Biotechnology.

[35]  J. Groten,et al.  Toxicology of simple and complex mixtures. , 2001, Trends in pharmacological sciences.

[36]  Robert Langer,et al.  Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.

[37]  T Görner,et al.  Lidocaine loaded biodegradable nanospheres. II. Modelling of drug release. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Rong Zhou,et al.  Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. , 2004, Academic radiology.

[39]  R. Sasisekharan,et al.  Exploiting nanotechnology to target cancer , 2007, British Journal of Cancer.

[40]  M. Prabhakaran,et al.  Nanotechnology for nanomedicine and delivery of drugs. , 2008, Current pharmaceutical design.

[41]  Mansoor M Amiji,et al.  Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.

[42]  R. C. Dutta Drug carriers in pharmaceutical design: promises and progress. , 2007, Current pharmaceutical design.

[43]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[44]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[45]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[46]  E. K. Park,et al.  Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. , 2004, Biomaterials.

[47]  R. Langer,et al.  [46] Immobilized heparin lyase system for blood deheparinization , 1988 .

[48]  Robert Langer,et al.  Multi-pulse drug delivery from a resorbable polymeric microchip device , 2003, Nature materials.

[49]  David M. Livingston,et al.  Cancer: Crossing over to drug resistance , 2008, Nature.

[50]  Amanda Paulovich,et al.  Cancer biomarkers: a systems approach , 2006, Nature Biotechnology.

[51]  J. McNamara,et al.  Cell-specific aptamers for targeted therapies. , 2009, Methods in molecular biology.

[52]  K Zygourakis,et al.  Computer-aided design of bioerodible devices with optimal release characteristics: a cellular automata approach. , 1996, Biomaterials.

[53]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[54]  Zachary Shriver,et al.  Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.

[55]  G. Robertson,et al.  Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development , 2008, Clinical Cancer Research.

[56]  J. Post,et al.  Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction , 2004, Nature Biotechnology.

[57]  Indu Bala,et al.  PLGA nanoparticles in drug delivery: the state of the art. , 2004, Critical reviews in therapeutic drug carrier systems.

[58]  Kewal K. Jain Ethical, Safety, and Regulatory Issues of Nanomedicine , 2008 .

[59]  P. Lin,et al.  Nanotechnology for antiangiogenic cancer therapy. , 2006, Nanomedicine.

[60]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[61]  Sophie Lanone,et al.  Potential uses of carbon nanotubes in the medical field: how worried should patients be? , 2007, Nanomedicine.

[62]  S. Ramalingam,et al.  Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. , 2009, Clinical lung cancer.

[63]  Harald zur Hausen,et al.  Infections Causing Human Cancer: ZUR HAUSEN:INFECT&CANCER O-BK , 2006 .

[64]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[65]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[66]  Chryso Kanthou,et al.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies , 2009, International journal of experimental pathology.

[67]  Shantesh Hede,et al.  "Nano": the new nemesis of cancer. , 2006, Journal of cancer research and therapeutics.

[68]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[69]  P Wust,et al.  Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[70]  A. Annapragada,et al.  Triggered release of ciprofloxacin from nanostructured agglomerated vesicles , 2007, International journal of nanomedicine.

[71]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[73]  R. Sasisekharan,et al.  A simple assay to probe disease-associated enzyme activity using glycosaminoglycan-assisted synthesized gold nanoparticles. , 2008, Organic & biomolecular chemistry.

[74]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[75]  Shuming Nie,et al.  Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. , 2009, Current drug discovery technologies.

[76]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[77]  F. Zhan,et al.  High heparanase activity in multiple myeloma is associated with elevated microvessel density. , 2003, Cancer research.

[78]  Z. Duan,et al.  Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.

[79]  V. Ling Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[80]  Corey Nislow,et al.  Combination chemical genetics. , 2008, Nature chemical biology.

[81]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  A. Krishan,et al.  Monitoring of cellular resistance to cancer chemotherapy. , 2002, Hematology/oncology clinics of North America.

[83]  Shiladitya Sengupta,et al.  Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis , 2004, Angiogenesis.

[84]  T. Haller,et al.  A voxel-based Monte Carlo model of drug release from bulk eroding nanoparticles. , 2010, Journal of nanoscience and nanotechnology.

[85]  M. Alonso,et al.  Design and characterisation of new nanoparticulate polymer blends for drug delivery , 2004, Journal of biomaterials science. Polymer edition.

[86]  C Malvy,et al.  Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[87]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[88]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[89]  Nelson Durán,et al.  New aspects of nanopharmaceutical delivery systems. , 2008, Journal of nanoscience and nanotechnology.

[90]  J. Rojo,et al.  Gold Glyconanoparticles as Water-Soluble Polyvalent Models To Study Carbohydrate Interactions. , 2001, Angewandte Chemie.

[91]  Robert Langer,et al.  Modeling of polymer erosion in three dimensions: Rotationally symmetric devices , 1995 .

[92]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[93]  L. Eaton World cancer rates set to double by 2020 , 2003, BMJ : British Medical Journal.

[94]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[95]  D. Tripathy Overcoming Fundamental Challenges in Systemic Therapy for Breast Cancer , 2009 .

[96]  S. Glotzer,et al.  Computer simulations of block copolymer tethered nanoparticle self-assembly. , 2006, The Journal of chemical physics.

[97]  Sanjiv S Gambhir,et al.  Drug delivery: keeping tabs on nanocarriers. , 2007, Nature nanotechnology.

[98]  B. Kamen,et al.  Receptor-mediated folate accumulation is regulated by the cellular folate content. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Delano,et al.  Emerging implications of nanotechnology on cancer diagnostics and therapeutics , 2006, Cancer.

[100]  C. Mohanty,et al.  Ligand-based targeted therapy for cancer tissue , 2009, Expert opinion on drug delivery.

[101]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Masato Takahashi,et al.  N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma , 2007, Molecular Cancer.

[103]  Lawrence Kulinsky,et al.  Development of integrated protection for a miniaturized drug delivery system , 2007 .

[104]  A. Saxena,et al.  Efficient computation of the structural phase behavior of block copolymers. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[105]  R. Sasisekharan,et al.  On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans , 2004, Angiogenesis.

[106]  Arie E. Kaufman,et al.  The CUBE workstation —a 3-D voxel-based graphics environment , 1988, The Visual Computer.

[107]  Hedi Mattoussi,et al.  Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy , 2004, Nature Medicine.

[108]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[109]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[110]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.